Jounce sags after ICOS mAb readout

Jounce Therapeutics Inc. (NASDAQ:JNCE) lost $6.22 (35%) to $11.45 Thursday after reporting data from the Phase I/II ICONIC trial evaluating the company's inducible T cell co-stimulator

Read the full 260 word article

User Sign In